Build status - In Progress

A Phase Ib Open-Label Multicenter Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

Recruiting
99 years or below
All
1 Location

Brief description of study

Requesting a reliance agreement with an external IRB. Study to evaluate pharmacokinetics, safety/tolerability, and immunogenicicty of ocrelizumab admistered subcutaneously in patients with MS. Pre-treated patients will be randomized (1:1) to dose-escalated, subcutaneous or IV administration. Treatment naive patients receive dose-escalated, subcutaneous administration only. All participants may then enter a dose continuation phase.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 Apr 2023. Study ID: 833380

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center